Atrasentan (hydrochloride), CAS 195733-43-8

Product Description: Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC50 of 0.0551 nM for ETA[1].

Applications: Cancer-programmed cell death

Formula: C29H39ClN2O6

Citations: Department Veterinary Clinical Medicine. University of Illinois. 2015./J Vet Intern Med. 2015 Nov;29(6):1584-94./Mol Immunol. 2019 Oct;114:10-18. /Commun Biol. 2022 Jul 28;5(1):750./Eur J Pharmacol. 2019 Mar 12;852:142-150.

References: [1]Yuyama H, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498(1-3):171-7./[2]Banerjee S, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 combination in prostate cancer. Cancer Res. 2007 Apr 15;67(8):3818-26./[3]Weiss J, et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol. 2011 Oct;68(4):1093-8.

CAS Number: 195733-43-8

Molecular Weight: 547.08

Compound Purity: 99.87

Research Area: Cancer; Endocrinology; Cardiovascular Disease

Solubility: 0.1 M HCL : < 1 mg/mL (ultrasonic;warming;adjust pH to 1 with HCl;heat to 60°C)/DMSO : 28.57 mg/mL (ultrasonic)/H2O : 0.5 mg/mL (ultrasonic;warming;adjust pH to 4 with HCl;heat to 60°C)

Target: Endothelin Receptor

• SKU: MEXHY-15403A-10.1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-15403A-10.1
• Package Unit: 10 mM/1 ml
• Quantity Unit: STK